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Peritoneal carcinomatosis is a frequent finding in gastric cancer associated with a poor prognosis. The features that enable
gastric tumors to disseminate are poorly understood until now. Previously, we showed elevated mRNA levels of
phosphoglycerate kinase 1 (PGK1), an adenosine triphosphate-generating enzyme in the glycolytic pathway, the chemokine
receptor 4 (CXCR4), the corresponding chemokine ligand 12 (CXCL12) and b-catenin in specimens from gastric cancer patients
with peritoneal carcinomatosis. In this study, the influence of PGK1 on CXCR4 and b-catenin was assessed as well as the
invasiveness of PGK1 overexpressing cancer cells. In this current study, we found that PGK1 regulates the expression of
CXCR4 and b-catenin at the mRNA and protein levels. On the other hand, CXCR4 regulates the expression of PGK1. Plasmid-
mediated overexpression of PGK1 dramatically increased the invasiveness of gastric cancer cells. Interestingly, inhibition of
CXCR4 in cells overexpressing PGK1 produced only a moderate reduction of invasiveness suggesting that, PGK1 itself has a
critical role in tumor invasiveness. Immunohistochemistry in specimens from diffuse gastric cancer patients also revealed an
overexpression of PGK1 in patients with development of peritoneal carcinomatosis. Therefore, PGK1 may be a crucial enzyme
in peritoneal dissemination. Together these findings suggest that the enhanced expression of PGK1 and its signaling targets
CXCR4 and b-catenin in gastric cancer cells promote peritoneal carcinomatosis. Thus, PGK1 may serve as prognostic marker
and/or be a potential therapeutic target to prevent dissemination of gastric carcinoma cells into the peritoneum.
Gastric cancer associated with peritoneal carcinomatosis is a
frequent cause of cancer-related death worldwide.1,2 Pres-
ently, there is no effective therapy, and the 5-year survival
rate is less than 2%.3 Previously, we studied the features that
enable gastric tumors to develop peritoneal dissemination.
Comparative microarray analyses were performed using
human specimens from consecutive gastric cancer patients
with peritoneal carcinomatosis versus gastric cancer patients
without peritoneal carcinomatosis. Tissues recovered from
individuals with peritoneal dissemination demonstrated sig-
nificantly higher mRNA levels of phosphoglycerate kinase 1
(PGK1), the chemokine receptor 4 (CXCR4), its ligand che-
mokine ligand 12 (CXCL12) and b-catenin.4 PGK1 is an
adenosine triphosphate (ATP)-generating enzyme of the gly-
colytic pathway that catalyzes the conversion of 1,3-diphos-
phoglycerate to 3-phosphoglycerate. In the nucleus, PGK1
affects DNA replication and repair.5 It is assumed that the
glycolytic pathway and glycolysis-related genes play an im-
portant role in tumorigenesis.
Solid tumor cells employ glycolytic enzymes, such as
PGK1, to generate ATP when their supply of oxygen is lim-
ited.6 Furthermore, PGK1 is involved in the onset of malig-
nancies, such as prostate, breast, pancreatic, multidrug
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resistant ovarian cancer and as recently reported, also in gas-
tric cancer.4,5,7–9 The human chemokine system contains
about 50 known ligands and 20 G protein-coupled receptors.
Chemokines and their receptors play important roles in
migration and activation of leukocytes, angiogenesis and tu-
mor growth.10 CXCR4, a 7-transmembrane G-protein-
coupled chemokine receptor and its ligand CXCL12 also
known as stromal-derived-factor-1 (SDF1) promote the pro-
gression and spreading of a number of malignant diseases
including prostate, nonsmall-cell lung, pancreatic, breast and
gastric cancer.2,4,11–14 CXCR4 is expressed on hematopoietic
and epithelial cancer cells, where it may aid in establishing
metastasis along a chemotactic gradient to organs expressing
CXCL12.15,16 Moreover, CXCL12-expressing cancer cells may
protect themselves from cytotoxic immune responses via
induction of apoptosis in cytotoxic T cells and inducing a
local Th1 ! Th2 shift in the tumor area.16–18 b-catenin, a
92-kDa protein, plays a central role in cadherin-based cell
adhesion processes, as a downstream effector in the Wnt-sig-
naling pathway and also as a potential downstream target of
PGK1.5,19 In gastric cancer, increased expression of b-catenin
is associated with enhanced proliferation, invasiveness, metas-
tasis, angiogenesis and drug resistance.4,20,21 There is a close
relationship between the regulation of the CXCR4/CXCL12
axis, b-catenin and PGK1 in prostate cancer.5 Interestingly,
as already mentioned earlier, we detected a strong overex-
pression of these genes in human primary gastric cancer
associated with development of peritoneal carcinomatosis.
Therefore, we studied the relationship between peritoneal dis-
semination through PGK1 and the regulation within its sig-
naling targets CXCR4, CXCL12 and b-catenin. Here, we
report that PGK1 appears to be a crucial enzyme for perito-
neal dissemination of gastric cancer in both CXCR4/




The human gastric adenocarcinoma cell line MKN-45 was
purchased (German Collection of Microorganisms and Cell
Cultures, Braunschweig, Germany) and cultured in RPMI
1640 medium supplemented with 20% fetal bovine serum
gold (Lonza, Basel, Switzerland). The cell line was selected
because of the distinct expression of PGK1 and the known
moderate expression of CXCR4, as described by Yasumoto
et al.2
Small interfering RNA knockdown of PGK1 and CXCR4
MKN-45 cells were seeded at 6  104 cells per well in 24-
well plates 24 hr before transfection. For transient transfec-
tion, cells were incubated with a complex of LipofectamineTM
RNAiMAX (Invitrogen, Carlsbad, CA) and small interfering
RNA (siRNA) in OptimemV
R
(Invitrogen) achieving final con-
centrations of 100 nM siRNA. The used siRNA was
siGENOMEV
R




SMARTpoolTM CXCR4 (L-005139-00-0005; Dharmacon, Chi-
cago, IL). Each pool consisted of 4 siRNAs targeting the gene
of interest. The siRNA ON-TARGETplusTM nontargeting
pool was used as a negative control. Ten hours after transfec-
tion medium was replaced by fresh culture medium. The cells
were harvested at distinct intervals after transfection.
Transfection and overexpression of PGK1
Plasmid transfection was carried out using the plasmid vector
(human Elongation Factor 1a Promoter-Internal Ribosome
Entry Sites) pEF-IRES containing PGK1. Briefly, 6  105
MKN-45 cells were seeded in 24-well plates 1 day before
transfection. Cells were transfected employing TfxTM-50
(Promega, Madison, WI) and 1 lg plasmid DNA was admin-
istered per well. The empty vector pEF-IRES was transfected,
serving as a negative control. Transfected cells were selected
with 5 lg/ml puromycin (AppliChem, Darmstadt, Germany)
24 hr after transfection.22
Quantitative real-time-PCR
RNA was extracted using the RNeasyV
R
Mini Kit (Qiagen, Hil-
den, Germany) assessing quality and quantity using a Nano-
Drop ND-1000 spectrophotometer (NanoDrop Technologies,
Wilmington, DE). Real-time PCR and complementary DNA
synthesis were performed as previously described.4 Relative
amounts of each gene proportional to an internal b-actin
control and hence fold changes were calculated using the
equation 2-DDCT, DCT ¼ CT(gene)  CT(b-actin) and
DDCT ¼ DCT(transfected)  DCT(control-transfected).23
Sequence specific primers were used as follows:
PGK1: 50-CATACCTGCTGGCTGGATGG-30 (forward)/
50-CCCACAGGACCATTCCACAC-30 (reverse), CXCR4: 50-
CAGTTTCAGCACATCATGGTTGG-30 (forward)/50-GTGA




Adherent MKN-45 cells were dissociated using Accutase
(PAA, Pasching, Austria), washed twice in phosphate buf-
fered saline at 4C and resuspended using AccuMax (PAA).
For every assay 5  105 cells were used. For extracellular
staining, a CXCR4 IgG2b monoclonal antibody (mAb; R&D,
Minneapolis, MN) was employed followed by labeling with a
phycoerythrin (R-PE) conjugated secondary antibody (Ab;
BD, Franklin Lakes, NJ). Intracellular staining was conducted
with the IntraPrepTM permeabilization reagent (Beckman
Coulter, Fullerton, CA) according to the manufacturer’s
instructions. A b-catenin Alexa Fluor 488 conjugated mAb
(R&D) was used. Incubation of all Ab was conducted for 20
min in the dark, followed by washing twice in flow cytometry
buffer (PBS, 0.1% BSA, 0.1% sodium azide). Cytometric anal-
ysis was performed using an Epics XL-MCL Flow Cytometer
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positive cells at the indicated excitation wavelengths, taking
into account the zero compensation of the nonspecific fluo-
rescence signal using MKN-45 cells previously incubated with
matching isotype control Ab (R&D). Analysis was performed
considering 2  105 events in the gate previously verified to
contain intact MKN-45 cells. The specific fluorescence index
(SFI; ratio of mean fluorescence intensity with antibody com-
pared to mean fluorescence intensity with isotype antibody)
was determined which underlined the specificity of all
findings.
Western blot analysis
Cells were harvested, washed and lysed in RIPA Buffer
(Pierce, Rockford, IL). For 5  105 cells 200 ll buffer was
used. PGK1 detection was performed with a polyclonal Ab
(Abnova, Taipei, Taiwan) at 1:500 dilution and anti-species-
specific horseradish peroxidase-conjugated secondary Ab
(Jackson Immuno Research, Suffolk, UK).
Invasion assay
Blind well chemotaxis chambers and polycarbonate filters
with 8-lm pore size (Neuro Probe, Gaithersburg, MD) were
used for the assay. Previously polycarbonate filters were
coated with growth factor reduced MatrigelTM (16.5 lg/filter;
BD Biosciences, Franklin Lakes, NJ). In the lower chamber
recombinant human CXCL12 (10 mM; R&D, Minneapolis,
MN) was added as a chemoattractant to NIH 3T3 (superna-
tant obtained from a mouse embryonic fibroblast cell line)
conditioned medium and 1  106 cells were added to the top
chamber. The chambers were incubated at 37C for 24 hr.
The top side of the filters was cleaned and the invading cells
were fixed with ethanol and stained by crystal violet. Invaded
cells were counted using a microscope (Axiovert 200, Axiovi-
sion software, 200 Zeiss, Goettingen, Germany). A neutral-
izing anti-CXCR4 Ab (25 lg/ml; R&D) added to the cells
before seeding them in the top chamber was used to inhibit
cell invasion. Each assay was performed using at least 4
replicates.
Cell-viability assay
Transfection was performed using 2  106 cells and a final
concentration of 100 nM siRNA for siPGK1 and nontarget-
ing control siRNA, as described earlier. Cells in the superna-
tant and adherent cells were collected and stained with 0.4%
trypan blue dye. Live and dead cells were determined by cell
counting in a Neubauer cytometer. Each point in time was
assessed in triplicate.
Patients and tissue specimens
Primary tumor samples from 10 patients who underwent lap-
arotomy for gastrectomy were investigated. Peritoneal carci-
nomatosis in diffuse gastric cancer specimens was histologi-
cally confirmed in 6 of the 10 patients [5 women, 1 men;
median age 69 years, range 29–80; Tumor, Node, Metastasis
(TNM)-categories according to the (Union internationale
Contre le Cancer): UICC pT2-category (n ¼ 1), pT3-category
(n ¼ 5), pN0-category (n ¼ 2), pN2-category (n ¼ 4), M1-
category (n ¼ 6)]. No peritoneal carcinomatosis was observed
in 4 of the 10 patients [3 women, 1 man; median age 72
years, range 62–77; TNM-categories according to the Union
Internationale Contre le Cancer (UICC): pT2-category (n ¼
1), pT3-category (n ¼ 3), pN1-categories (n ¼ 3), pN2-cate-
gory (n ¼ 1), M0-category (n ¼ 4)]. All of the tumor speci-
mens were obtained at the Department of General, Visceral
and Transplant Surgery at the University of Tuebingen, Ger-
many. The specimens were snap-frozen in liquid nitrogen
and stored at 80C until use. Each tumor sample was sub-
jected to frozen sectioning, stained with haematoxylin and
eosin, and reevaluated by an experienced surgical pathologist.
All of patients provided informed consent to participate in
the study, which was approved by the local ethics committee
(168/2005).
Immunohistochemistry
For the immunohistochemical examination, 2 lm tissue
slides from formalin fixed, paraffin embedded tumor tissue
were used. In brief, sections were deparaffined in xylene,
rehydrated and epitop retrieval was performed in citrate
buffer (pH 6) using the Pascal pressure chamber (Dako,
DakoCytomation GmbH, Hamburg, Germany) for 2 min at
125C. After blocking endogenous peroxidase with 3% H2O2,
primary antibody (dilution 1:200; clone: sc-48342; Santa Cruz
Biotechnology Inc, Santa Cruz, CA) was incubated for 60
min. Detection was carried out using EnvisionTM goat-anti-
mouse secondary antibody (Dako, DakoCytomation GmbH,
Hamburg, Germany) for 60 min followed by incubation with
diaminobenzidine (DAB). Nuclear as well as cytoplasmic
staining was considered specific, and a moderate to strong
expression was considered as positive.
Statistical analyses
Mean and standard deviation (SD) were calculated for all
variables. Intergroup statistical significance was determined
using the Student’s t test, and p < 0.05 was considered statis-
tically significant.
Results
PGK1 regulates CXCR4 and b-catenin expression
To detect that the CXCR4/CXCL12 axis and b-catenin are
regulated by PGK1 expression, quantitative real time-PCR
(qRT-PCR), flow cytometry and western blots were per-
formed after siRNA targeting of PGK1 in MKN45 gastric ad-
enocarcinoma cells. QRT-PCR revealed a considerable down-
regulation of PGK1, CXCR4 and b-catenin expression (Fig.
1a). CXCL12 mRNA was not detectable in the MKN45 cell
line. Western blot analysis was conducted for PGK1 and flow
cytometry for CXCR4 and b-catenin with the objective to
confirm the mRNA expression data. Western blot showed a
considerable downregulation of PGK1 expression in siPGK1-
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reference (Fig. 1c). b-catenin and CXCR4 protein expression
were decreased in MKN45 siPGK1 cells (Fig. 1f). The distinct
time intervals can be explained by the fact that the effects
detected on mRNA levels are translated with a certain delay
into effects on protein levels. Hence, the most pronounced
effects on protein levels were observed at later points of time.
PGK1 and CXCR4 regulate their expression reciprocally
To determine whether the inhibition of CXCR4 regulates
PGK1 expression, siRNA was used to decrease CXCR4
expression. Inhibition of CXCR4 reduced both, mRNA
expression of PGK1 (Fig. 1b) and PGK1 protein levels (Fig.
1d) suggesting that, reciprocal regulation exists between
PGK1 and CXCR4.
Cell-viability assay
Overall proliferation and survival of the siPGK1-treated cells
and the corresponding control siRNA treated cells were eval-
uated by the trypan blue assay more than 4 days following
transfection (Fig. 1e). The number of viable and cells unable
to exclude the dye in both groups were comparable (the
transfected with siPGK1 and siControl). This suggests that
the knockdown of PGK1 is not responsible for relevant dif-
ferences in cell death.
Overexpression of PGK1 regulates CXCR4 and b-catenin
expression
As elevated PGK1 levels are a prominent feature of peritoneal
dissemination in gastric cancer, overexpression of PGK1 was
induced in MKN45 cells stably transfected with PGK1 pEF-
IRES plasmid. Controls included cells transfected with an
empty pEF-IRES vector and qRT-PCR, flow cytometry and
western blots were conducted. QRT-PCR demonstrated sig-
nificant increases in PGK1, CXCR4 and b-catenin expression
(Fig. 2a, right panel). Western blot analysis revealed that
overexpression of PGK1 in pEF-IRES cells was achieved
using b-actin as a reference (Fig. 2b). In these cells, signifi-
cantly higher protein levels of CXCR4 and b-catenin were
detected compared to the corresponding controls (Fig. 2c).
These data suggest that PGK1 is a regulatory molecule of
CXCR4 and b-catenin.
Overexpression of PGK1 increases the invasiveness of
gastric cancer in vitro
To test the hypothesis that PGK1 overexpression promotes
invasion, invasion assays were performed in which a basement
membrane matrix (e.g., MatrigelTM) was used as a barrier and
NIH-3T3 conditioned medium with recombinant human
CXCL12 was used as the chemoattractant. PGK1 MKN45/pEF-
IRES cells invaded dramatically stronger than that of the
MKN45/control cells (Fig. 3a). To elucidate if the invasiveness
of these cells was mainly caused by PGK1 or CXCR4, the
assays were performed in the presence or absence of anti-
CXCR4 specific blocking antibodies. Under these conditions,
invasion was only moderately inhibited (Fig. 3b).
Figure 1. Small interfering RNA-mediated PGK1 gene silencing reduces
CXCR4 and b-catenin expression inMKN45 cells. MKN45 cells treated
with control siRNA or PGK1 siRNA pool (a) or CXCR4 siRNA pool (b) were
assessed for PGK1, CXCR4 and b-cateninmRNA levels by qRT-PCR at 28,
34 and 40 hr (a) or 52, 82 and 92 hr (b) post-transfection, mRNA levels
are given as relative changes compared to correspondingMKN45 cells
treatedwith non-targeting control siRNA resulting in 100%. (c) Cell lysates
of theMKN45 control cells or PGK1-siRNA cells were examined for PGK1
protein expression by immunoblot using b-actin as a reference. Lysates
were prepared 46, 64 and 76 hr post-transfection. (d) Cell lysates of the
MKN45 control cells or MKN45CXCR4-siRNA cells were examined for
PGK1 protein expression byWestern blot using b-actin as a reference.
Lysates were prepared 70, 82 and 106 hr post-transfection. (e) Cell
proliferation and viability of PGK1siRNA and control siRNA treated cells
were determined by the trypan blue dye exclusionmethod. Total cell
numbers of living and dead cells are given at 24, 48, 72, 96 and 120 hr
and represent themean numbers of 3 independent experiments. (f)
CXCR4 and b-catenin protein levels inMKN45 siControls orMKN45
siPGK1 cells were determined by FACS analysis 76 hr post-transfection.
Representative FACS profiles are shown, and the respectivemedians of
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Overexpression of PGK1 by immunohistochemistry in
human diffuse gastric cancer
To further explore PGK1 expression in gastric cancer, immu-
nohistochemical staining of diffuse primary gastric cancer
specimens from 10 patients was performed. Peritoneal carci-
nomatosis was histologically confirmed in 6 of the 10 patients
at the time of surgery. Five of these patients with peritoneal
carcinomatosis showed a medium to strong nuclear staining
for PGK1, whereas cytoplasmic staining was less intense or
absent. Only in 1 sample in which peritoneal carcinomatosis
was histologically confirmed, a weak staining in very few cells
was detected. In patients in whom no peritoneal carcinoma-
tosis was histologically confirmed, all of the samples showed
only a weak or no staining for PGK1 (Fig. 4).
Discussion
In this investigation, the relationship between tumorigenesis,
glycolytic metabolism and chemokine signaling was exam-
ined. Using siRNA targeting PGK1 in a gastric cancer cell
line, we discovered that the expression of the chemokine re-
ceptor CXCR4 and the Wnt-pathway member b-catenin were
linked to PGK1 expression. Flow cytometry confirmed the
regulation of CXCR4 and b-catenin on protein level. Simi-
larly, when CXCR4 was targeted by siRNA, PGK1 expression
was diminished. Hence, PGK1 and CXCR4 are able to regu-
late each other in a costimulating way. Likewise, assuming
that elevated levels of PGK1 are crucial for peritoneal dissem-
ination in gastric cancer, the effects of overexpression of
PGK1 were further evaluated. PGK1 overexpression in gastric
cancer cells resulted in significantly elevated mRNA expres-
sion and protein levels of CXCR4 and b-catenin. In vitro
invasion assays underlined these findings showing that cells
invaded more dramatically when PGK1 was overexpressed.
Blocking CXCR4 in the invasion assay revealed only a mod-
erate inhibition of invading cells. Performing immunohisto-
chemical staining of diffuse human primary gastric cancer
specimens, we further detected that patients with peritoneal
dissemination showed a moderately elevated to stronger
staining compared to the primary tumors without peritoneal
dissemination. These results lead to 2 conclusions: First, there
is a direct connection between PGK1 signaling and CXCR4
and b-catenin expression. Second, overexpression of PGK1
leads to signaling through CXCR4 and perhaps through other
unknown pathways resulting in changes in the metastatic
rate, invasiveness and tumor growth in gastric cancer.
Furthermore, it is known that results obtained using this
kind of assay show a strong correlation between the ability of
tumor cells to invade in vitro and their invasive behavior
in vivo, which validates this assay as an index for invasive
potential. Together, these data suggest that overexpression of
PGK1 enhances gastric cancer cells to invade and metastasize
in a CXCR4/CXCL12-dependent and furthermore particularly
independent way. Advanced gastric cancer is often associated
with metastasis and peritoneal carcinomatosis. Although the
reasons for dissemination and invasiveness are not clear, sev-
eral mechanisms may account for the complex phenomenon.
One recently reported mechanism associated with peritoneal
carcinomatosis was that elevated levels of CXCR4 were
detected in gastric tumors combined with high
Figure 2. PGK1 overexpression increases CXCR4 and b-catenin
levels in MKN45 cells. (a) PGK1 mRNA overexpression in MKN45
cells stably transfected with PGK1 pEF-IRES plasmid normalized to
MKN45 pEF-IRES control pools (equals to 100%) as well as CXCR4
mRNA levels were assessed by qRT-PCR. Mean expression levels of
PGK1, CXCR4 and b-catenin mRNA levels in pools #1–#3 are
presented in the right panel (*p < 0.05). The left panel depicts the
single pools. (b) Cell lysates of the MKN45 control pools or the
MKN45 PGK1 pools were examined for PGK1 protein expression by
immunoblot using b-actin as a reference. (c) MKN45/PGK1pools
#1–#3 or MKN45/control pools were assessed for CXCR4 and b-
catenin protein by flow cytometry. Representative flow cytometry
profiles of the MKN45/PGK1pools and MKN45/control pools are
shown and the respective medians of fluorescence and SFI values
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Figure 3. PGK1 overexpression dramatically increases the invasiveness of gastric cancer cells: modulation by inhibition of CXCR4. (a)
Invasion for 24 hr was assessed in 3 independent MKN45 puromycin control pools and in MKN45/PGK1pools #1–#3. Data are expressed
as means of the control pools #1–#3 and MKN45/PGK1pools #1–#3 and SD (*p < 0.05). (b) MKN45/PGK1pool#3 cells were treated with
isotype control or anti-CXCR4 antibody. (a and b) Representative photomicrographs of the results of the invasion assays are depicted.
Figure 4. PGK1 overexpression in human diffuse gastric cancer with peritoneal carcinomatosis. Immunohistochemical staining for PGK1 in
diffuse gastric cancer patients with (a and b) and without (c and d) peritoneal carcinomatosis. (a) and (b) show a strong staining in most
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concentrations of CXCL12 in malignant ascites fluids of these
patients.2 It is assumed that CXCR4 positive cells are
attracted along a chemotactic gradient to organs expressing
its ligand CXCL12.16 Furthermore, CXCL12-expressing can-
cer cells may protect themselves from a cytotoxic immune
response via induction of apoptosis in cytotoxic T cells and
inducing a local Th1 ! Th2 shift in the tumor area.15,17,18 A
second mechanism of cell proliferation, angiogenesis, tumor
invasion and metastasis in gastric cancer is mediated through
b-catenin.4,20,21 A third and novel mechanism is supported
by the PGK1 data. Our previous work showed that patients
with gastric cancer developing peritoneal carcinomatosis,
compared to patients without further dissemination, dis-
played much higher mRNA levels of CXCR4/CXCL12, b-cat-
enin and the glycolytic enzyme PGK1.4 Our new data con-
cerning PGK1 and its regulatory effects, even though based
on protein levels rather than activity per se, provide compre-
hensive evidence of the ‘‘Warburg effect.’’ In the 1950s, War-
burg quantified the impaired mitochondrial function and
increased dependence on glycolysis as a source of energy,
using ascitic cancer cells.24 Meanwhile it is largely accepted
and shown that solid tumor cells employ glycolytic enzymes,
such as PGK1, to produce ATP when their supply of oxygen
is limited.6 PGK1 is known to be involved in the onset of
several malignancies, such as breast, pancreatic and ovarian
cancer.7–9 A significant association between PGK1 expression
and the CXCR4/CXCL12 axis was recently reported in pros-
tate cancer cell lines, in which overexpression of PGK1
increased the metastatic rate.5 One of our most striking find-
ings was that PGK1 seems to be a central molecule concern-
ing tumor invasion and metastasis in gastric cancer (Fig. 5).
Overexpression of PGK1 resulted in significantly elevated
expression and protein levels of CXCR4 and b-catenin and
enhanced invasiveness in MatrigelTM assays. High levels of
CXCL12, via CXCR4 overexpression, might protect cancer
cells (as already described) from immune responses and ele-
vated CXCR4 levels multiplying the metastatic process.15 On
the other hand, there is evidence that low levels of extracellu-
lar CXCL12 may augment metastatic potential towards envi-
ronments with higher levels of CXCL12.16 As PGK1 was
shown to regulate b-catenin in prostate cancer, it is possible
that an enhanced expression of PGK1 is able to decrease can-
cer cell–cell-adhesion linked to Wnt signaling and thus
increase cell migration.5 Those results previously obtained are
underlined by our recent findings in human gastric cancer
patients.4 In summary, the results presented here show that
high levels of PGK1 are essential for tumor growth and me-
tastasis. These data further show a direct relationship
between PGK1 signaling CXCR4 and b-catenin expression
and represent a promising pathway concerning peritoneal
carcinomatosis and metastasis in gastric cancer. These find-
ings support the comprehension between glucose metabolism
and chemokine function and might serve as potential thera-
peutic targets to prevent metastasis of gastric carcinoma cells.
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